The RCI - Regensburg Centre for Interventional Immunology (foundation public law) researches and develops new immunotherapies for the treatment of tumours, autoimmune diseases and transplant rejections.

The Chair for Genetic Immunotherapy at the RCI, Prof. Dr. Hinrich Abken, is recruiting a

**Post-doctoral Scientist in “CAR redirected T cells” (all gender, reference number HA-2021-5)**

with a track record in the field of T cell immunology, with substantial experience working with recombinant immune cell receptors, in particular chimeric antigen receptors (CARs), non-viral gene transfer technologies, and/or animal models. The position is within the framework of the International Research Consortium “NICE” (“Nanomaterials for efficacious cancer immunotherapy: in vivo engineering of immune cells and tumor microenvironment”) and is remunerated on the TV-L salary scale (TV-L EG 13). The funding period of the NICE consortium in total is 6 years.

The Chair for Genetic Immunotherapy investigates novel strategies in redirected T cell therapy, specifically applying CAR and TRUCK engineered T cells for the treatment of tumors and auto-immune diseases. It is becoming increasingly clear that apart from current ex vivo manufacturing processes, non-viral gene transfer technologies (e.g., sleeping-beauty) together with nano-technologies will change the landscape towards in vivo immune cell engineering technologies. We offer a post-doctoral position within the Consortium to further develop the non-viral gene transfer concept toward novel engineering technologies for redirecting T cells.\(^1\)\(^-\)\(^3\)

**Responsibilities include, but are not limited to:**

- Design and conduct research projects aiming at developing nano-particle based, non-viral gene transfer technologies for immune cells
- Establishing “synthetic immunology” strategies to provide novel functions to T cells
- Writing scientific manuscripts and grant applications
- Presenting data on international meetings

**Requirement:**

We are looking for a highly motivated and enthusiastic individual able to work independently as well as a part of an interdisciplinary international team

- PhD, MD or equivalent in life sciences with a strong background in molecular biology and/or gene transfer technologies
Experience in experimental immunology, in particular in working with genetically engineered T cells

Excellent communication skills and proficiency in English are mandatory

We offer:

We offer the opportunity to work within an international consortium on genetically engineered CAR/TRUCK T cells for translation into adoptive cell therapy which is currently one of the most exciting emerging fields in the treatment of cancer, autoimmunity, chronic inflammation and allergy. We provide cutting-edge technologies in T cell immunology, recombinant protein engineering, microscopy and functional immune cell recording.

The RCI follows the goal of professional equality for all genders and therefore strongly encourages qualified women to apply. In addition, the RCI supports work-family balance.

The RCI is an equal opportunity employer and candidates with disabilities will be given preference, provided they are equally qualified.

Please note that expenses that may arise in the context of an eventual job interview cannot be reimbursed.

For more information please contact Prof. Dr. Hinrich Abken (e-mail: hinrich.abken@ukr.de; phone: +49 941 944 38111).

If you are interested and open to new professional challenges, we would be delighted to receive your application including your statement of interest, curriculum vitae, certificates, expected availability date, list of publications and 2-3 references. Please apply via our homepage www.rcii.de quoting the reference HA-2021-5.

Application deadline is November 14th, 2021.

Project related References:
3. Hombach et al., IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. Mol. Ther., in press